Colhoun, Helen MLeiter, Lawrence AMüller-Wieland, DirkCariou, BertrandRay, Kausik KTinahones, Francisco JDomenger, CatherineLetierce, AlexiaIsrael, MarcSamuel, RitaDel Prato, Stefano2023-02-082023-02-082020-02-08http://hdl.handle.net/10668/15076Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and apolipoprotein B (ApoB) are the preferred therapeutic targets for mixed dyslipidemia. Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that effectively reduces low-density lipoprotein cholesterol (LDL-C), non-HDL-C, ApoB, and lipoprotein(a) (Lp[a]), and is well-tolerated in individuals with T2DM. The previously reported open-label ODYSSEY DM-DYSLIPIDEMIA trial data demonstrated the effects of alirocumab on individuals with non-HDL-C ≥ 100 mg/dL and TGs ≥ 150 and  Alirocumab significantly reduced non-HDL-C [LS mean difference (standard error (SE)), - 35.0% (3.9)], ApoB [LS mean difference (SE), - 34.7% (3.6)], LDL-C [LS mean difference (SE), - 47.3% (5.2)], LDL particle number [LS mean difference (SE), - 40.8% (4.1)], and Lp(a) [LS mean difference (SE), - 29.9% (5.4)] versus usual care from baseline to Week 24 (all P  Alirocumab is an effective therapeutic option for individuals with T2DM, TGs ≥ 200 mg/dL, and HDL-C enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AlirocumabDM-DYSLIPIDEMIADiabetes mellitusHDL-CNon-HDL-CODYSSEYPCSK9TriglyceridesType 2 diabetesUsual careAgedAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsBiomarkersCholesterol, HDLDiabetes Mellitus, Type 2DyslipidemiasFemaleHumansMaleMiddle AgedPCSK9 InhibitorsProtease InhibitorsTime FactorsTreatment OutcomeTriglyceridesresearch article32035487open access10.1186/s12933-020-0991-11475-2840PMC7007683https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-020-0991-1.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007683/pdf